For: | Asami K, Atagi S. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. World J Clin Oncol 2014; 5(4): 646-659 [PMID: 25302168 DOI: 10.5306/wjco.v5.i4.646] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v5/i4/646.htm |
Number | Citing Articles |
1 |
Shanthi Kanthala, Sandeep Pallerla, Seetharama Jois. Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors. Future Oncology 2015; 11(5): 865 doi: 10.2217/fon.14.312
|
2 |
Haijian Wu, Yan Liu, Xiao Ou Shu, Qiuyin Cai. MiR-374a suppresses lung adenocarcinoma cell proliferation and invasion by targetingTGFAgene expression. Carcinogenesis 2016; 37(6): 567 doi: 10.1093/carcin/bgw038
|
3 |
BO ZHOU, JUN NIE, WEIDONG YANG, CHENHONG HUANG, YE HUANG, HONGFEI ZHAO. Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients. Oncology Letters 2016; 11(2): 1413 doi: 10.3892/ol.2015.4066
|
4 |
Christina Stache, Christiane Bils, Rudolf Fahlbusch, Jörg Flitsch, Michael Buchfelder, Harald Stefanits, Thomas Czech, Udo Gaipl, Benjamin Frey, Rolf Buslei, Annett Hölsken. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin. Neurosurgical Focus 2016; 41(6): E14 doi: 10.3171/2016.9.FOCUS16316
|
5 |
Kai Wu, Jiachen Li, Yu Qi, Chunyang Zhang, Dengyan Zhu, Donglei Liu, Song Zhao. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p. Biomedicine & Pharmacotherapy 2019; 116: 108995 doi: 10.1016/j.biopha.2019.108995
|
6 |
STEFAN HARTMANN, ROMAN C. BRANDS, NORA KÜCHLER, ANDREAS FUCHS, CHRISTIAN LINZ, ALEXANDER C. KÜBLER, URS D.A. MÜLLER-RICHTER. Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer. Oncology Letters 2015; 10(2): 1211 doi: 10.3892/ol.2015.3345
|
7 |
Keara L. Redmond, Anastasia Papafili, Mark Lawler, Sandra Van Schaeybroeck. Overcoming Resistance to Targeted Therapies in Cancer. Seminars in Oncology 2015; 42(6): 896 doi: 10.1053/j.seminoncol.2015.09.028
|
8 |
Xiaoyan Ma, Min Shan, Yunlong Lu. Design and Synthesis of Gefitinib Derivatives as Potential Drugs fo r
Cancer Treatment: Antiproliferative Activity, Molecular Docking, and
ADMET Prediction. Letters in Drug Design & Discovery 2024; 21(9): 1555 doi: 10.2174/1570180820666230810164118
|
9 |
Nina Shaban, Dmitri Kamashev, Aleksandra Emelianova, Anton Buzdin. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. Cells 2023; 13(1): 47 doi: 10.3390/cells13010047
|
10 |
L Jin, Y Liu, X Wang, X Qi. Immunohistochemical analysis and comparison of napsin A, TTF1, SPA and CK7 expression in primary lung adenocarcinoma. Biotechnic & Histochemistry 2018; 93(5): 364 doi: 10.1080/10520295.2018.1444790
|
11 |
Xuefeng Zhou, Jialong Guo, Yanmei Ji, Gaofeng Pan, Tao Liu, Hua Zhu, Jinping Zhao. Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma. Molecular Cancer Research 2016; 14(5): 448 doi: 10.1158/1541-7786.MCR-15-0480
|
12 |
Bin Wang, Lixiao Liu, Jinting Wu, Xiaolu Mao, Zhen Fang, Yingyu Chen, Wenfeng Li. Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.711142
|
13 |
Jinsong Li, Huayun Deng, Meichun Hu, Yuanzhang Fang, Amanda Vaughn, Xiaopan Cai, Leqin Xu, Wei Wan, Zhenxi Li, Shijie Chen, Xinghai Yang, Song Wu, Jianru Xiao. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR. Oncotarget 2015; 6(9): 6749 doi: 10.18632/oncotarget.3155
|
14 |
Karla A. Ruiz-Ceja, Yolanda I. Chirino. Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. Biomedicine & Pharmacotherapy 2017; 90: 24 doi: 10.1016/j.biopha.2017.03.018
|